This study suggests thatco-administering IFN-α with a replication-conditional oncolytic adenovirus mayboth reduce the toxicity of IFN-α and increase its efficacy, by locally highconcentrations of IFN-α at the site of the tumor, while systemic levelsremained low. The gene discussed is IFNA17; the disease is neoplasm.